RealSeq Biosciences
RealSeq Biosciences develops the proprietary RiboMarker® RNA fragmentomics platform, which enables discovery of novel RNA biomarkers by analyzing RNA fragments undetectable by traditional methods. Their technology combines library construction, next-generation sequencing (NGS), and AI-powered bioinformatics to unlock RNA analytes for broad diagnostic applications including oncology, infectious disease, and agricultural biotechnology. Founded in 2019 with NIH funding, the company offers sequencing services, library preparation kits, and collaborates with industry and research partners to advance RNA-based diagnostics. Their platform provides deeper transcriptome insights and complements DNA analysis, aiming to improve diagnostics and health outcomes globally.
RealSeq Biosciences
RealSeq Biosciences develops the proprietary RiboMarker® RNA fragmentomics platform, which enables discovery of novel RNA biomarkers by analyzing RNA fragments undetectable by traditional methods. Their technology combines library construction, next-generation sequencing (NGS), and AI-powered bioinformatics to unlock RNA analytes for broad diagnostic applications including oncology, infectious disease, and agricultural biotechnology. Founded in 2019 with NIH funding, the company offers sequencing services, library preparation kits, and collaborates with industry and research partners to advance RNA-based diagnostics. Their platform provides deeper transcriptome insights and complements DNA analysis, aiming to improve diagnostics and health outcomes globally.